The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34+ Cell Administration in Patients With Refractory Angina

JACC: Cardiovascular Interventions

Volumn 9, Issue 15, 2016, Pages 1576-1585

  Povsic, Thomas J ^a   Henry, Timothy D ^b   Traverse, Jay H ^c   Fortuin, F David ^d   Schaer, Gary L ^e   Kereiakes, Dean J ^f   Schatz, Richard A ^g   Zeiher, Andreas M ^h   White, Christopher J ⁱ   Stewart, Duncan J ^j   Jolicoeur, E Marc ^k   Bass, Theodore ^l   Henderson, David A ^m   Dignacco, Patricia ^a   Gu, Ziangoiong ^a   Al Khalidi, Hussein R ^a   Junge, Candice ⁿ   Nada, Adel ^o   Hunt, Andrea S ^p   Losordo, Douglas W ^q  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c ABBOTT NORTHWESTERN HOSPITAL   (United States)

^d MAYO CLINIC HOSPITAL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f CHRIST HOSPITAL   (United States)

^g SCRIPPS CLINIC   (United States)

^h GOETHE UNIVERSITY   (Germany)

ⁱ OCHSNER MEDICAL CENTER   (United States)

^j OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^k MONTREAL HEART INSTITUTE   (Canada)

^l UNIVERSITY OF FLORIDA   (United States)

^m Cardiology Research Associates   (United States)

ⁿ AMGEN INC   (United States)

^o INTELLIA THERAPEUTICS   (United States)

^p Baxalta US Inc   (United States)

^q Caladrius Biosciences   (United States)

more..

Author keywords

angina; angiogenesis; CD34+; interventional therapy; progenitor cell; stable coronary disease; stem cell

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE; BIOLOGICAL MARKER; CD34 ANTIGEN;

ADULT; ANGINA PECTORIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CELL THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANGINA; RISK FACTOR; ADVERSE EFFECTS; AGED; ANGIOGENESIS; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONVALESCENCE; EARLY TERMINATION OF CLINICAL TRIAL; ENDOTHELIAL PROGENITOR CELL; EXERCISE TOLERANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; STEM CELL TRANSPLANTATION; TIME FACTOR; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGINA PECTORIS; ANTIGENS, CD34; BIOMARKERS; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; ENDOTHELIAL PROGENITOR CELLS; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; RECOVERY OF FUNCTION; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; UNITED STATES;

EID: 84992109650     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.05.003     Document Type: Article

References (35)

1. 1 Henry, T.D., Satran, D., Jolicoeur, E.M., Treatment of refractory angina in patients not suitable for revascularization. Nat Rev Cardiol 11 (2014), 78–95.
2. 2 Williams, B., Menon, M., Satran, D., et al. Patients with coronary artery disease not amenable to traditional revascularization: Prevalence and 3-year mortality. Catheter Cardiovasc Interv 75 (2010), 886–891.
3. 3 McGillion, M., L'Allier, P.L., Arthur, H., et al. Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement. Can J Cardiol 25 (2010), 399–401.
4. 4 Andréll, P., Ekre, O., Grip, L., et al. Fatality, morbidity and quality of life in patients with refractory angina pectoris. Int J Cardiol 147 (2011), 377–382.
5. 5 Henry, T.D., Satran, D., Hodges, J.S., et al. Long-term survival in patients with refractory angina. Eur Heart J 34 (2013), 2683–2688.
6. 6 Povsic, T.J., Broderick, S., Anstrom, K.J., et al. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc, 4, 2015.
7. 7 Weisz, G., Généreux, P., Iñiguez, A., et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 387 (2016), 136–145.
8. 8 Arora, R.R., Chou, T.M., Jain, D., et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 33 (1999), 1833–1840.
9. 9 Jimenez-Quevedo, P., Gonzalez-Ferrer, J.J., Sabate, M., et al. Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial. Circ Res 115 (2014), 950–960.
10. 10 Tse, H.-F., Thambar, S., Kwong, Y.-L., et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 28 (2007), 2998–3005.
11. 11 van Ramshorst, J., Bax, J.J., Beeres, S.L.M.A., et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia. JAMA 301 (2009), 1997–2004.
12. 12 Kawamoto, A., Tkebuchava, T., Yamaguchi, J.-I., et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107 (2003), 461–468.
13. 13 Kawamoto, A., Iwasaki, H., Kusano, K., et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 114 (2006), 2163–2169.
14. 14 Iwasaki, H., Kawamoto, A., Ishikawa, M., et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 113 (2006), 1311–1325.
15. 15 Losordo, D.W., Henry, T.D., Davidson, C., et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 109 (2011), 428–436.
16. 16 Losordo, D.W., Schatz, R.A., White, C.J., et al. Intramyocardial transplantation of autologous cd34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115 (2007), 3165–3172.
17. 17 Wang, S., Cui, J., Peng, W., Lu, M., Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology 117 (2010), 140–147.
18. 18 Fisher, S., Dorre, C., Brunskill, S.J., Mathur, A., Martin-Rendon, E., Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS ONE, 9, 2013 e64669.
19. 19 Khan, A.R., Farid, T.A., Pathan, A., et al. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res 118 (2016), 984–993.
20. 20 Kandala, J., Upadhyay, G.A., Pokushalov, E., Wu, S., Drachman, D.E., Singh, J.P., Meta-Analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 112 (2013), 217–225.
21. 21 Li, N., Yang, Y.-J., Zhang, Q., Jin, C., Wang, H., Qian, H.-Y., Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials. Can J Cardiol 29 (2013), 908–914.
22. 22 Povsic, T.J., Junge, C., Nada, A., et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J 165 (2013), 854–861.e2.
23. 23 Povsic, T.J., Losordo, D.W., Story, K., et al. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilisation, aphaeresis and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J 164 (2012), 689–697.e3.
24. 24 Chaitman, B.R., Skettino, S.L., Parker, J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004), 1375–1382.
25. 25 Henry, T.D., Annex, B.H., McKendall, G.R., et al. The VIVA trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis. Circulation 107 (2003), 1359–1365.
26. 26 Henry, T.D., Grines, C.L., Watkins, M.W., et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 50 (2007), 1038–1046.
27. 27 Leon, M.B., Kornowski, R., Downey, W.E., et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 46 (2005), 1812–1819.
28. 28 Losordo, D.W., Vale, P.R., Hendel, R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105 (2002), 2012–2018.
29. 29 Henry, T.D., Schaer, G.L., Traverse, J.H., et al. Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant, 2016 May 4 [E-pub ahead of print].
30. 30 Iltis, A.S., Stopping trials early for commercial reasons: the risk–benefit relationship as a moral compass. J Med Ethics 31 (2005), 410–414.
31. 31 Drüeke, T.B., Descamps-Latscha, B., Locatelli, F., Stopping a medical research project for financial reasons. Nephrol Dial Transplant 18 (2003), 1982–1983.
32. 32 Mark, D.B., O'Connor, C.M., When business and science clash, how can we avoid harming patients? The case of AVOID-HF∗. J Am Coll Cardiol HF 4 (2016), 106–108.
33. 33 Psaty, B.M., Rennie, D., Stopping medical research to save money: a broken pact with researchers and patients. JAMA 289 (2003), 2128–2131.
34. 34 Ashcroft, R., Responsibilities of sponsors are limited in premature discontinuation of trials. BMJ, 323, 2001, 53.
35. 35 Evans, S., Popcock, S., Societal responsibilities of clinical trial sponsors: lack of commercial pay off is not a legitimate reason for stopping a trial. BMJ 322 (2001), 569–570.